- Company
- Ildong expands collaboration with Evotec
- by Kim, Jin-Gu Jul 23, 2020 06:11am
- Ildong announced on the 21st that it will expand its cooperation with global new drug development company Evotec to conduct clinical trials on NASH (non-alcoholic steatohepatitis) treatment research project 'ID11903'. Evotech's drug research platform, 'INDiGO', is used to conduct various tasks necessary for clinical entry, such as nonclini
- Company
- Rx amount for Choline alfoscerate is the largest ever
- by Chon, Seung-Hyun Jul 22, 2020 06:16am
- Rx market for brain function-enhancing drug 'Choline alfoscerate' has grown significantly. Despite the controversy over the effectiveness and the bad news of COVID-19, the rate was over &8361;200 billion the first half of this year and continued to rise. The monthly prescription amount was &8361;40 billion. Not only Daewoong Bio and Chon
- Policy
- HIRA says antibiotic prescription in flu down by 0.12%
- by Lee, Hye-Kyung Jul 22, 2020 06:16am
- [A look into Drug Reimbursement Evaluation Report 2019] Last year’s antibiotic prescription rate on acute upper respiratory tract infection fell by 0.21 percent from the previous year and was recorded at 38.30 percent. The number of drug item per prescription also climbed down by 0.05 item from 3.72 items in 2018 to 3.67 items in 2019
- Company
- Samsung Biologics signed a contract with Lundbeck
- by Jul 22, 2020 06:16am
- Samsung Biologics announced on the 20th that it has signed a contract for biopharmaceutical contract worth &8361; 19.3 billion with global pharmaceutical company Lundbeck. The two companies signed their first contract on September 27, last year, and the size of the contract increased to &8361;19.3 billion ($15.99 million) under further
- Company
- Hanmi returns with salt-modified Champix generic
- by Kim, Jin-Gu Jul 22, 2020 06:15am
- Hanmi Pharmaceutical is trying the Champix (varenicline) generic market for the second time. Initially, the license on the Korean company’s generic Nocotine tablet was revoked, but it came back to the market with Nocotine S tablet with different substance. On July 20, Hanmi Pharmaceutical announced the launch of a varenicline generic No
- Company
- Will interferon have the potential to treat mild COVID-19?
- by Jul 22, 2020 06:15am
- Efforts have been made to continue to identify the potential for interferon preparations as a treatment for COVID-19. Interferon is one of the antiviral immune substances and increases the activity of innate immune cells (T cells, B cells, macrophages, etc.) to strengthen the human immune system. As the existing antiviral drugs such as K
- Company
- Ranitidine risk comes back as opportunity for Boryung
- by An, Kyung-Jin Jul 21, 2020 06:10am
- Korea’s Ministry of Food and Drug Safety (MFDS) has banned all sales of ranitidine drugs from Sept. 26 last year. After collecting and investigating ranitidine drugs, the ministry discovered unacceptable level of N-nitrosodimethylamine (NDMA). Also a month later, the ministry banned the sales of 13 nizatidine drugs with the same reason.
- Company
- Celltrion, commercially produce CT-P59 starting in September
- by An, Kyung-Jin Jul 21, 2020 06:10am
- Seo Jung-jin, Chairman at Celltrion Pharm, announced that the company will begin the production of COVID-19 antiviral antibody treatment that have entered the clinical stage. It is intended to quickly enter the commercialization stage by completing the verification of the adequacy and validity of production facilities early on. On the mor
- Policy
- Chong Kun Dang generic to open Atozet generic market
- by Lee, Tak-Sun Jul 21, 2020 06:10am
- As Atozet’s post-marketing surveillance (PMS) expiration is approaching in next year, Chong Kun Dang is closely eyeing on the follow-on drug market. While many of Atozet (atorvastatin plus ezetimibe) generic makers are currently developing evidences like bioequivalence test to seek approval after Jan. 22 next year when the original’s P
- Policy
- Celltrion's CT-P59 was approved for phase I clinical trial
- by Lee, Tak-Sun Jul 21, 2020 06:10am
- Celltrion's development of COVID-19 antiviral antibody treatment has been approved for clinical trials in Korea. The MFDS announced that it has approved a phase I clinical trial on the 17th for 'CT-P59', a domestically developed COVID-19 antiviral antibody treatment. As a result, a total of 13 clinical trials (11 treatments, 2 vaccines) w
